Pedro Mediano
Lecturer (Assistant Professor) in the Department of Computing at Imperial College London
Data updated
Research Footprint
Pedro Mediano appears in 10 tracked papers (2022–2026), most studied alongside LSD, Psilocybin and Ketamine, across Neuroimaging & Brain Measures, Healthy Volunteers and Depressive Disorders.
Most-cited paper: Canalization and plasticity in psychopathology (101 citations).
Frequent co-authors: Robin Carhart-Harris, Fernando Rosas and Christopher Timmermann.
Background & Research
Pedro Mediano is a lecturer in the Department of Computing at Imperial College London and is affiliated with the Consciousness and Cognition Lab at the University of Cambridge. His work sits at the intersection of consciousness science, information theory, complexity science, machine learning, and altered states of consciousness; he previously completed a PhD at Imperial and a postdoctoral position at Cambridge.
Key Impact
He is a computational neuroscience and information-theory researcher whose work has been directly cited in psychedelic science on whole-brain modeling, external stimulation during psychedelic states, and consciousness-related dynamics.
Collaboration Network
29 collaborators· click a node to visit their profile
Full network →Compounds
Topics
Top Collaborators
Affiliations
Institutions, companies, and organisations Pedro Mediano is associated with.
Imperial College London
academicThe Centre for Psychedelic Research, led by Professor David Nutt and Dr. David Erritzoe, focuses heavily on the action of psychedelic drugs in the brain and their clinical utility as aides to psychotherapy. Thanks to their extensive neuroimaging studies, this group has proposed vital mechanisms for how psychedelics work, including the Entropic Brain Theory and REBUS (RElaxed Beliefs Under Psychedelics).
View stakeholder →University of Cambridge
academicThe Cambridge Psychedelic Research Group (CPRG) brings together scientists, psychiatrists, and clinical psychologists to rigorously advance psychedelic-assisted therapy for mental health. The CPRG initiated its first clinical trials focusing on psychedelic-assisted therapy for post-traumatic stress disorder (PTSD). Currently, the center is initiating additional trials to investigate the therapeutic potential of psilocybin for adults suffering from treatment-resistant depression and generalized anxiety disorder.
View stakeholder →